UnitedHealth Group's stock declined after a report indicated a broader criminal investigation by the U.S. Department of Justice into the company, now expanding to include Optum Rx. The probe's expansion suggests increased scrutiny of the company's practices. Shares closed lower following the news, which has raised concerns among investors. The investigation's scope and potential implications for UnitedHealth are still unfolding, highlighting the ongoing legal challenges facing the healthcare giant.